KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 120 filers reported holding KEROS THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 0.09 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $653,510 | +46813.9% | 14,300 | -67.3% | 0.00% | -50.0% |
| Q3 2023 | $1,393 | -49.3% | 43,700 | -36.1% | 0.00% | -50.0% |
| Q2 2023 | $2,748 | -46.9% | 68,400 | -43.5% | 0.00% | -42.9% |
| Q1 2023 | $5,171 | +17.2% | 121,100 | +31.8% | 0.01% | +16.7% |
| Q4 2022 | $4,413 | -99.9% | 91,900 | -5.5% | 0.01% | +20.0% |
| Q3 2022 | $3,657,000 | -6.6% | 97,200 | -31.4% | 0.01% | 0.0% |
| Q2 2022 | $3,915,000 | +1259.4% | 141,700 | +2573.6% | 0.01% | – |
| Q1 2022 | $288,000 | -70.4% | 5,300 | -78.4% | 0.00% | -100.0% |
| Q3 2021 | $972,000 | +36.5% | 24,572 | +143.3% | 0.00% | 0.0% |
| Q4 2020 | $712,000 | +4.2% | 10,100 | -42.9% | 0.00% | 0.0% |
| Q3 2020 | $683,000 | +189.4% | 17,700 | +181.0% | 0.00% | – |
| Q2 2020 | $236,000 | – | 6,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 292,833 | $17,134,000 | 5.65% |
| Deep Track Capital, LP | 1,300,000 | $76,063,000 | 5.37% |
| Octagon Capital Advisors LP | 340,214 | $19,906,000 | 3.87% |
| Opaleye Management Inc. | 265,750 | $15,549,000 | 3.30% |
| First Light Asset Management, LLC | 552,098 | $32,303,000 | 2.31% |
| Altium Capital Management LP | 116,000 | $6,787,000 | 1.87% |
| Nantahala Capital Management | 796,698 | $46,615,000 | 1.64% |
| Orbimed Advisors | 1,679,417 | $98,263,000 | 1.26% |
| Darwin Global Management, Ltd. | 111,500 | $6,524,000 | 1.00% |
| Parkman Healthcare Partners LLC | 69,861 | $4,088,000 | 0.90% |